Glenn David - 09 Feb 2026 Form 4 Insider Report for PHIBRO ANIMAL HEALTH CORP (PAHC)

Role: Chief Financial Officer
Signature: /s/ Judith Weinstein, as Attorney-in-Fact for Glenn David
Issuer symbol: PAHC
Transactions as of: 09 Feb 2026
Net transactions value: -$646,758
Form type: 4
Filing time: 11 Feb 2026, 16:15:07 UTC
Previous filing: 19 Aug 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
David Glenn	Chief Financial Officer	300 FRANK W. BURR BLVD., STE 21, TEANECK	/s/ Judith Weinstein, as Attorney-in-Fact for Glenn David	11 Feb 2026	0001606256

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PAHC	Class A Common Stock	Options Exercise		+30,000	+86%		64,845	09 Feb 2026	Direct	F1
transaction	PAHC	Class A Common Stock	Other	$646,758	-12,528	-19%	$51.62	52,317	11 Feb 2026	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PAHC	Restricted Stock Units	Options Exercise	$0	-30,000	-11%	$0.000000	240,000	09 Feb 2026	Class A Common Stock	30,000		Direct	F1, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares were issued in settlement of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock.
F2	Represents shares sold in a broker assisted cashless exercise program to satisfy tax withholding obligations upon the receipt of Class A Common Stock in connection with the vesting and settlement of the RSUs.
F3	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.54 to $52.03. The reporting person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4	On February 9, 2024 (the "Grant Date"), the reporting person was granted 300,000 RSUs pursuant to the Issuer's 2008 Incentive Plan and an RSU award agreement (the "Award Agreement").
F5	Pursuant to the Award Agreement, (i) 150,000 RSUs are subject to time vesting (collectively, the "Time Vesting RSUs") and vest in equal installments on each of the first five anniversaries of the Grant Date, subject to continued service through each such vesting date, and (ii) 150,000 RSUs are subject to performance vesting (collectively, the "Performance Vesting RSUs") and vest (with linear interpolation to apply for achievement between increments) based upon achievement of the arithmetic average of the Issuer's closing stock price per share for each trading day in the 90-calendar day period ending five years from the Grant Date, from $20 to $60 and above, subject to Mr. David's continued employment on such date. Time Vesting RSUs and Performance Vesting RSUs, in each case, are subject to earlier vesting upon certain qualifying termination events.